| |
Time (min)
|
|---|
|
0
|
15
|
30
|
60
|
90
|
120
|
|---|
|
Adrenocorticotropic hormone (pg/ml)
|
2.1
|
3.5
|
4.0
|
3.4
|
2.9
|
2.2
|
|
Cortisol (μg/dl)
|
< 0.2
|
< 0.2
|
< 0.2
|
< 0.2
|
< 0.2
|
< 0.2
|
|
Thyroid-stimulating hormone (μIU/ml)
|
5.47
|
22.86
|
33.95
|
28.66
|
23.64
|
17.65
|
|
Growth hormone (ng/ml)
|
7.67
|
19.96
|
34.68
|
38.76
|
37.53
|
21.17
|
|
Prolactin (ng/ml)
|
22.6
|
75.6
|
94.4
|
84.6
|
61.2
|
44.6
|
|
Luteinizing hormone (mIU/ml)
|
10.4
|
21.8
|
30.9
|
45.3
|
47.9
|
43.1
|
|
Follicle-stimulating hormone (mIU/ml)
|
32.8
|
36.2
|
33.6
|
36.6
|
45.6
|
45.5
|
- The following synthetic hypothalamic hormones were intravenously administered in the morning (9 a.m.): human corticotropin-releasing hormone (CRH; 100 μg), growth hormone-releasing factor (GRF; 100 μg), thyrotropin-releasing hormone (TRH; 500 μg), and luteinizing hormone-releasing hormone (LHRH; 100 μg)
- The hormone replacement therapy with oral levothyroxine (50 μg/day) for primary hypothyroidism was discontinued on day 2 after admission, and the patient’s serum levels of free thyroxine (1.26 ng/dl) and free triiodothyronine (2.77 pg/ml) were measured just before the drug administration
